Cboe Global Markets vs CME
CBOE and CME side by side, both in security & commodity brokers, dealers, exchanges & services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBOE and CME compare
CME is the larger company, worth 3.1 times as much as Cboe Global Markets ($109B against $35.0B).
On earnings, Cboe Global Markets is cheaper: it trades at 23.9× trailing earnings, against 25.7× for CME.
Cboe Global Markets grew revenue faster over the last twelve months (14.3% versus 5.1% for CME).
Both pay dividends: Cboe Global Markets yields 0.69% and CME 3.7%.
Cboe Global Markets scores higher on the StockData Score (23 against 9 for CME), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBOE | CME |
|---|---|---|
| Size and price | ||
| Market cap | $35.0B | $109B |
| Share price | $335.53 | $303.14 |
| Change, 1 year | 44.2% | 15.9% |
| Change, 5 years | 152% | 36.7% |
| Beta (5Y) | 0.25 | 0.36 |
| Employees | 1,661 | 3,875 |
| StockData Score | ||
| Total score | 23 (better) | 9 |
| Valuation score | 3 (better) | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 6 (better) | 2 |
| Health score | 6 (better) | 5 |
| Dividend score | 4 (better) | 1 |
| Valuation | ||
| P/E | 23.9× (better) | 25.7× |
| P/S | 6.6× (better) | 16.1× |
| P/B | 5.9× | 4.1× (better) |
| EV/EBITDA | 16.6× (better) | 24.2× |
| P/FCF | 13.9× (better) | 25.9× |
| PEG | 0.35 (better) | 1.75 |
| FCF yield | 7.2% (better) | 3.9% |
| Fair value | $323.98 | $250.81 |
| Margin of safety | −3.6% (better) | −20.9% |
| Growth | ||
| Revenue growth (TTM) | 14.3% (better) | 5.1% |
| Revenue growth, 5Y average | 6.6% (better) | 6.0% |
| Net income growth (TTM) | 50.6% | – |
| EPS growth (TTM) | 51.0% (better) | 14.1% |
| EPS growth, 5Y average | 19.5% (better) | 13.7% |
| Profitability | ||
| Gross margin | 53.9% | – |
| Operating margin | 36.4% | 65.1% (better) |
| Net margin | 28.0% | – |
| FCF margin | 47.9% | 62.2% (better) |
| Return on equity | 27.4% | – |
| Return on invested capital | 36.2% (better) | 13.5% |
| Financial health | ||
| Debt / equity | 0.24 (better) | 0.00 |
| Net debt / EBITDA | −0.62 | – |
| Interest coverage | 36.3× | – |
| Current ratio | 1.61 (better) | 1.02 |
| Altman Z-score | 5.82 (better) | 0.56 |
| Piotroski F-score | 9 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.69% | 3.7% (better) |
| Payout ratio | 21.4% | – |
| Years of dividend growth | 11 (better) | 0 |
| Dividend growth, 5Y average | 11.6% (better) | −3.3% |
| Buyback yield | 0.38% | – |
| Shareholder yield | 1.1% | 3.7% (better) |
| Ownership | ||
| Held by institutions | 89.2% | 89.5% |
| Held by insiders | 0.25% | 0.34% |
| Insider net buying, 12 months | −$2.3M (better) | −$30.4M |
| Superinvestors holding | 1 | 5 (better) |
| Short interest, % of float | 3.2% | 1.5% |
Go deeper
- CBOE stock overview
- CBOE income statement
- CBOE valuation and score
- CME stock overview
- CME income statement
- CME valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.